Dianax is a technology company.
Dianax has raised $780K across 1 funding round.
Dianax has raised $780K in total across 1 funding round.
Dianax S.R.L. is an Italian medtech startup based in Milan, specializing in portable, smartphone-synced diagnostic devices for point-of-need testing.[1][2] The company develops "lab-on-a-chip" solutions using patented BioMEMS technology that analyzes a drop of blood or fluid in minutes via microfluidics, electrophoresis, and electrochemistry, enabling screening, diagnosis, and monitoring of chronic diseases, antibiotic stewardship, and other health priorities.[2][4] Dianax serves healthcare providers, public/private facilities, and potentially home users by delivering sustainable, accurate diagnostics anywhere—from clinics to remote areas—generating revenue through test sales and exploring further opportunities.[1][3]
These pocket-sized tools integrate digital pathology to enhance diagnosis quality, decentralizing lab capabilities for faster clinical decisions and better patient outcomes in resource-limited settings.[1][2]
Dianax emerged from Milan, Italy, as an innovative player in mobile in-vitro diagnostics, though specific founding year and founders are not detailed in available records.[2] The company's idea stems from advancing "lab-on-a-chip" technology to miniaturize complex lab processes, allowing protein purification from a fraction of a drop of fluid and biomarker analysis via smartphone synergy.[2][4] Early focus on cost-effective, patented BioMEMS innovations in microfluidics and electrochemistry marked pivotal traction, positioning Dianax for global health applications like rapid chronic disease monitoring.[2] Its presence on startup ecosystems like Padda Health and Dealroom indicates growing investor interest in its decentralized diagnostics model.[1][3][4]
Dianax rides the wave of point-of-care diagnostics and personalized medicine, fueled by demand for decentralized testing post-pandemic and in chronic care.[2] Timing aligns with biotech trends in microfluidics and BioMEMS, enabling faster decisions in antibiotics stewardship and remote monitoring amid aging populations and healthcare access gaps.[1][2] Market forces like rising chronic disease prevalence and smartphone ubiquity favor its model, reducing lab bottlenecks and costs while influencing ecosystems through networks like Padda Health for startups and investors.[1][3] By democratizing high-accuracy diagnostics, Dianax contributes to global health equity, bridging research and patient care in biotech.[2]
Dianax is poised for scale through partnerships with healthcare institutions and ventures, expanding its lab-on-a-chip portfolio to more biomarkers and AI-enhanced analysis.[2][3] Trends like telehealth growth, regulatory nods for mobile diagnostics, and AI microfluidics will accelerate adoption, potentially boosting revenue via subscriptions or global distribution.[3] Its influence may evolve from niche innovator to key player in sustainable medtech, transforming point-of-need testing worldwide—echoing its core mission of pocket-sized, life-saving diagnostics anytime, anywhere.[1][2]
Dianax has raised $780K in total across 1 funding round.
Dianax's investors include RedSeed Ventures.
Dianax has raised $780K across 1 funding round. Most recently, it raised $780K Seed in September 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2015 | $780K Seed | RedSeed Ventures |